AstraZeneca PLC
30 November 2001
Announcement to LSE Friday, 30 November 2001 at 09:00 GMT
AstraZeneca Annual Business Review
On Monday 3 December 2001, AstraZeneca is holding an Annual Business Review
for analysts and investors at the Conference Forum, London, and again on
Wednesday 5 December 2001 in New York at the Equitable Center.
The London presentations start at 08:30 GMT and can be listened to via a
global teleconference for which the numbers are in the UK: 08700 559 361, for
Europe: +49 6936 506 9600 and for the US: +1 212 346 0166. A live webcast of
the London presentations only will be available on the AstraZeneca website.
The New York presentations on 5 December start at 08:30EST, and can be
listened to via a global teleconference for which the numbers are in the UK:
08700 559 361, for Europe: +49 6936 506 9600 and for the US: +1 888 303 1619.
These numbers, as well as details of the replay facility available through 15
December 2001, are available on the Investor Relations part of the AstraZeneca
website at www.astrazeneca.com.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.